84 filings
Page 4 of 5
8-K
eurfjeckhwso u31booh
10 Aug 20
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
5:21pm
8-K
sp23xh
14 Jul 20
Entry into a Material Definitive Agreement
6:08am
8-K
851p2j1b
13 Jul 20
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon
6:05am
8-K
ziiuc
1 Jun 20
Departure of Directors or Certain Officers
8:04am
8-K
vkq2ly
21 May 20
Submission of Matters to a Vote of Security Holders
8:17am
8-K
8gt6ftvq1u0sc
13 May 20
Equillium Reports First Quarter 2020 Financial Results
4:10pm
8-K
71i admfiyq7cd
24 Apr 20
Departure of Directors or Certain Officers
4:30pm
8-K
y6nv ocz39h4dmf
30 Mar 20
Entry into a Material Definitive Agreement
4:15pm
8-K
zwgo33w
26 Mar 20
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
4:10pm
8-K
t83ijc6cc1 l3bj9741c
12 Dec 19
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to
7:05am
8-K
2hp5ke0tjzf1nagyfl
27 Nov 19
Other Events
4:08pm
8-K
3nbruf35
12 Nov 19
Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights
4:10pm
8-K
67l8bp 9h4ctyx
1 Oct 19
Entry into a Material Definitive Agreement
4:10pm
8-K
i3t6x92h9hfk t6
12 Aug 19
Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights
4:10pm
8-K
0lerx2nx019gk7y415m
12 Jun 19
Submission of Matters to a Vote of Security Holders
4:10pm
8-K
76q76fmb737b h9
13 May 19
Equillium Reports First Quarter 2019 Financial Results and Recent Highlights
4:15pm
8-K
xyxpd 6ro26zl6mtxo6
1 May 19
Regulation FD Disclosure
12:00am
8-K
054qbtg
27 Mar 19
Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
4:08pm
8-K
jx6k2 xes0crjb3z
26 Feb 19
Results of Operations and Financial Condition
4:05pm
8-K
l49j6qh4yemmans2o5qc
20 Feb 19
Material Modifications to Rights of Security Holders
4:08pm